Accustem Sciences Inc · OTC:ACUT
Accustem Sciences — Investor Presentation (October 2023)
16 slides from Accustem Sciences's investor presentation, October 2023
Slide 1: AccuStem
ACCU — A ACCUSTEM
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The
Slide 3: Company Overview
COMPANY OVERVIEW Our mission at AccuStem is to provide proprietary diagnostic tools that address unanswered clinical questions and have therapeutic-like market and margin opportunities As the only known company evaluating tumor “stemness,” our initial focus will be the commercialization of StemPrint
Slide 4: AccuStem Roadmap to Commercialization
ACCUSTEM ROADMAP TO COMMERCIALIZATION Our focus is commercializing a proprietary genomic test in breast cancer representing an estimated market opportunity greater than $1.3B annually that does not require FDA clearance PHASE 1 PHASE 2 PHASE 3 TARGET CANCER CMS ASSET (ANALYTICAL (CLINICAL (CLINICAL
Slide 5: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 6: The Role of "Stemness" in Cancer
THE ROLE OF “STEMNESS” IN CANCER The cancer stem cell hypothesis is a fundamental concept in cancer biology • Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely • This hypothesis an
Slide 7: Validation of StemPrintER in Breast Cancer
VALIDATION OF STEMPRINTER IN BREAST CANCER 1 2 N= 574 N= 644 N= 344 N= 432 StemPrintER is highly prognostic for StemPrintER outperformed the market leader- outcomes in early-stage breast cancer OncotypeDx- in the TransATAC cohort 1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022
Slide 8: Clinical Decision Making in Breast Cancer
CLINICAL DECISION MAKING IN BREAST CANCER BIOPSY SURGERY THERAPY Clinical Questions What is the subtype of cancer? Mastectomy vs. lumpectomy? Adjuvant Chemotherapy? Is patient a candidate for NAC? Sentinel node vs. full axillary Hormone Therapy? How aggressive is the cancer? dissection? Radiation Th
Slide 9: Breast Cancer Genomics Industry
BREAST CANCER GENOMICS INDUSTRY AccuStem Exact Sciences Agendia Hologic Myriad Genetics Veracyte Breast Cancer Product StemPrintER OncotypeDX MammaPrint Endopredict Prosigna Index Global Serviceable 798,000 562,000 562,000 562,000 562,000 562,000 Market Reimbursement (CMS) N/A $3873 $3873 $3873 $387
Slide 10: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay • Planning to build on current research • Proven leadership team with nearly 60 from Istituto Europeo di of stemness across different tumor combined years of experience in the On
Slide 11: Opportunity in Lung Cancer
OPPORTUNITY IN LUNG CANCER 2M+ new lung cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER may inform treatment planning in patients with early stage lung cancer • By evaluating the underlying "stem" biology of tumors, we believe our test will
Slide 12: Opportunity in Prostate Cancer
OPPORTUNITY IN PROSTATE CANCER 1.4M+ new prostate cancer diagnoses annually • No genomic tests to inform approach to definitive treatment (e.g., surgery, radiation, ablation) StemPrintER may inform treatment planning in patients with localized prostate cancer • By evaluating the underlying "stem" bi
Slide 13: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay • Planning to build on current • Proven leadership team with nearly from Istituto Europeo di research of stemness across 60 combined years of experience in Oncologia (IEO) differ
Slide 14: Our Leadership Team and Approach: A Proven Track Record
OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD WENDY BLOSSER, CEO KEEREN SHAH, CFO JOE FLANAGAN, CBO ✓ 23 years of success building ✓ 20 years of experience in ✓ 15 years of strategic expertise with organizations in Oncology and controllership, financial planning and successful product laun
Slide 15: Investment and Company Highlights
INVESTMENT AND COMPANY HIGHLIGHTS ✓ Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies ✓ Only known company with novel diagnostic platform evaluating tum
Slide 16: Thank You for Your Consideration
THANK YOU FOR YOUR CONSIDERATION [email protected] | Accustem.com
AccuStem Sciences — Investor Presentation (October 2023) on 6ix